- Conditions
- Head and Neck Cancer
- Interventions
- porfiromycin, radiation therapy
- Drug · Radiation
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Peoria, Illinois • Dallas, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 32,907
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Post Treatment Lyme Syndrome (PTLS), Chronic Pain
- Interventions
- Milnacipran and D-cycloserine
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Depressive Disorder, Major, Suicidal
- Interventions
- SLS-002, Placebo, Standard of care, Intranasal device
- Drug · Other · Device
- Lead sponsor
- Seelos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 21
- States / cities
- Orange, California • Panorama City, California • San Diego, California + 18 more
- Conditions
- Psoriasis
- Interventions
- JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more
- Conditions
- Immune Thrombocytopenia
- Interventions
- Avatrombopag, Placebo
- Drug
- Lead sponsor
- Sobi, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Long Beach, California • Orange, California + 18 more
- Conditions
- Graft vs. Host Disease
- Interventions
- Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
- Interventions
- Everolimus (RAD001), Everolimus Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
- Conditions
- Major Depression
- Interventions
- Pramipexole, Escitalopram
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- JNJ-38431055 Dose 1, Sitagliptin 100 mg, Placebo, JNJ-38431055 Dose 2
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 25 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- Fort Myers, Florida • San Antonio, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Filgotinib, Placebo to match filgotinib, csDMARDs
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 55
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
- Conditions
- AIDS
- Interventions
- Blood collection, GSK HIV vaccine 732462
- Procedure · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Fort Lauderdale, Florida • Orlando, Florida + 7 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Sertraline, Levetiracetam, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Ovarian Cancer
- Interventions
- Dexamethasone, Placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 59 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Infantile Colic
- Interventions
- chamomile/probiotic arm, Placebo of chamomile/probiotic arm
- Dietary Supplement
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 3 Weeks to 16 Weeks
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Preterm Birth, Child Development
- Interventions
- Docosahexaenoic Acid + Arachidonic Acid (DHA+AA), Placebo
- Drug · Dietary Supplement
- Lead sponsor
- Sarah Keim
- Other
- Eligibility
- 10 Months to 16 Months
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Alzheimer's Disease
- Interventions
- LY2062430, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 13 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Newton, Kansas • Syracuse, New York • Ellensburg, Washington
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Nicotinamide riboside, Placebo capsules
- Drug
- Lead sponsor
- Donna Hammond, PhD
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea
- Interventions
- Tadalafil, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 35 Years to 89 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Decatur, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Obstructive Sleep Apnea, Hypertension
- Interventions
- Lorundrostat, Placebo
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 27
- States / cities
- Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Inositol supplement, Placebo supplement
- Dietary Supplement
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 36 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Obstructive Sleep Apnea
- Interventions
- AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test
- Drug · Diagnostic Test
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more
- Conditions
- Major Depressive Disorder
- Interventions
- Dose-matched placebo, Vilazodone
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • Encino, California • New Port Beach, California + 11 more
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- placebo, Sorafenib
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois